Ravi V Shah1, Matthew A Allison2, Joao A C Lima3, Siddique A Abbasi4, Morgana Mongraw-Chaffin2, Michael Jerosch-Herold5, Jingzhong Ding6, Matthew J Budoff7, Venkatesh L Murthy8. 1. Department of Cardiology and Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Road, Suite 454-East, Boston, MA, 02215, USA. rshah1@bidmc.harvard.edu. 2. Department of Family and Preventative Medicine, University of California-San Diego, San Diego, CA, USA. 3. Cardiology Division, Johns Hopkins Medical Institute, Baltimore, MD, USA. 4. Department of Cardiology and Medicine, Brown University, Providence, RI, USA. 5. Non-Invasive Cardiovascular Imaging, Brigham and Women's Hospital, Boston, MA, USA. 6. Department of Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA. 7. Department of Cardiology and Medicine, University of California-Los Angeles, Los Angeles, CA, USA. 8. Cardiovascular Medicine Division, Department of Medicine, Nuclear Medicine and Cardiothoracic Imaging Divisions, Department of Radiology, University of Michigan, 1338 Cardiovascular Center, Ann Arbor, MI, USA. vlmurthy@med.umich.edu.
Abstract
OBJECTIVE: To measure association between hepatic fat and albuminuria (an early marker of renal injury) in individuals without diabetes or hypertension. METHODS: 2,281 individuals in the Multi-Ethnic Study of Atherosclerosis without diabetes or hypertension, renal disease, or excess alcohol consumption underwent computed tomography (CT) for assessment of liver attenuation (marker of hepatic lipid content) and urinalysis (for albuminuria) at initial study visit, with assessment of incident and prevalent albuminuria by logistic regression in follow-up. RESULTS: After adjustment for age, gender, race, smoking, blood pressure, insulin resistance, and body mass index, individuals with less liver fat (higher liver CT attenuation) had a lower probability of having albuminuria at Exam 1 (OR per 10 unit increase in attenuation 0.77, 95 % CI 0.61-0.97, P = 0.02). At median 9.3 years follow-up, albuminuria was identified in 129 individuals were (5.8 %). In fully adjusted models (with age, smoking, body mass index, blood pressure, diabetes and hypertension as time-dependent covariates), lower liver attenuation (greater liver fat) was associated with higher risk of incident albuminuria (OR 0.79, 95 % CI 0.66-0.94, P = 0.008). CONCLUSIONS: Hepatic attenuation is associated with prevalent and incident albuminuria, an early, potent risk factor for renal risk in a population not clearly at risk for future renal failure.
OBJECTIVE: To measure association between hepatic fat and albuminuria (an early marker of renal injury) in individuals without diabetes or hypertension. METHODS: 2,281 individuals in the Multi-Ethnic Study of Atherosclerosis without diabetes or hypertension, renal disease, or excess alcohol consumption underwent computed tomography (CT) for assessment of liver attenuation (marker of hepatic lipid content) and urinalysis (for albuminuria) at initial study visit, with assessment of incident and prevalent albuminuria by logistic regression in follow-up. RESULTS: After adjustment for age, gender, race, smoking, blood pressure, insulin resistance, and body mass index, individuals with less liver fat (higher liver CT attenuation) had a lower probability of having albuminuria at Exam 1 (OR per 10 unit increase in attenuation 0.77, 95 % CI 0.61-0.97, P = 0.02). At median 9.3 years follow-up, albuminuria was identified in 129 individuals were (5.8 %). In fully adjusted models (with age, smoking, body mass index, blood pressure, diabetes and hypertension as time-dependent covariates), lower liver attenuation (greater liver fat) was associated with higher risk of incident albuminuria (OR 0.79, 95 % CI 0.66-0.94, P = 0.008). CONCLUSIONS: Hepatic attenuation is associated with prevalent and incident albuminuria, an early, potent risk factor for renal risk in a population not clearly at risk for future renal failure.
Authors: Meredith C Foster; Shih-Jen Hwang; Joseph M Massaro; Udo Hoffmann; Ian H DeBoer; Sander J Robins; Ramachandran S Vasan; Caroline S Fox Journal: Obesity (Silver Spring) Date: 2010-12-23 Impact factor: 5.002
Authors: Joseph Yeboah; Alain G Bertoni; David M Herrington; Wendy S Post; Gregory L Burke Journal: J Am Coll Cardiol Date: 2011-07-05 Impact factor: 24.094
Authors: Geoffrey H Tison; Michael J Blaha; Matthew J Budoff; Ronit Katz; Juan J Rivera; Alain G Bertoni; Nathan D Wong; Roger S Blumenthal; Moyses Szklo; John Eng; Russell Tracy; Khurram Nasir Journal: Atherosclerosis Date: 2011-07-06 Impact factor: 5.162
Authors: Matthew A Allison; David A Bluemke; Robyn McClelland; Mary Cushman; Michael H Criqui; Joseph F Polak; Joao A Lima Journal: Am J Cardiol Date: 2013-05-24 Impact factor: 2.778
Authors: Ravi V Shah; Siddique A Abbasi; Bobak Heydari; Carsten Rickers; David R Jacobs; Lu Wang; Raymond Y Kwong; David A Bluemke; Joao A C Lima; Michael Jerosch-Herold Journal: J Am Coll Cardiol Date: 2013-04-23 Impact factor: 24.094
Authors: Pranav S Garimella; Joachim H Ix; Ronit Katz; Michael G Shlipak; Michael H Criqui; David S Siscovick; Holly Kramer; Christopher T Sibley; Mark J Sarnak Journal: Am J Kidney Dis Date: 2014-07-03 Impact factor: 8.860
Authors: R V Shah; V L Murthy; M A Allison; J Ding; M Budoff; A C Frazier-Wood; J A C Lima; L Steffen; D Siscovick; K L Tucker; P Ouyang; S A Abbasi; K Danielson; M Jerosch-Herold; D Mozaffarian Journal: Nutr Metab Cardiovasc Dis Date: 2015-12-29 Impact factor: 4.222
Authors: Ravi Shah; Venkatesh Murthy; Michael Pacold; Kirsty Danielson; Kahraman Tanriverdi; Martin G Larson; Kristina Hanspers; Alexander Pico; Eric Mick; Jared Reis; Sarah de Ferranti; Elizaveta Freinkman; Daniel Levy; Udo Hoffmann; Stavroula Osganian; Saumya Das; Jane E Freedman Journal: Diabetes Care Date: 2017-02-09 Impact factor: 19.112